Entrada Therapeutics Inc. (TRDA)

AI Score

Unlock

8.71

0.00 (0.00%)

At close: Apr 24, 2025, 1:09 PM

Entrada Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.

Fiscal Year	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021	Q1 2021	Q4 2020	Q3 2020	Q2 2020	Q1 2020
Period Ending	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Revenue	37.4M	19.57M	94.69M	59.12M	41.85M	43.73M	18.17M	25.26M	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cost of Revenue	n/a	900K	900K	934K	736K	800K	700K	541K	525K	500K	500K	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Gross Profit	37.4M	18.67M	93.79M	58.19M	41.11M	42.94M	17.47M	24.72M	-525K	-500K	-500K	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Operating Income	-5.87M	-21.66M	53.42M	21.11M	4.91M	14.01M	-16.3M	1.32M	-25.58M	-25.94M	-23.58M	-22.15M	-18.46M	-14.36M	-9.91M	-8.39M	-8.65M	-6.97M	-5.52M	-5.52M
Interest Income	5.13M	5.77M	4.37M	4.21M	4.29M	4.05M	4.22M	2.66M	950K	799K	403K	480K	n/a	n/a	9K	13K	n/a	n/a	n/a	n/a
Pretax Income	-739K	-15.89M	57.79M	25.33M	9.2M	18.06M	-12.08M	-3.12M	-24.63M	-25.14M	-23.18M	-21.67M	-18.45M	-14.43M	-9.9M	-8.38M	-8.67M	-6.99M	-5.43M	-5.43M
Net Income	1.13M	-14.03M	55.03M	23.5M	-9.54M	35.46M	-25.93M	-6.67M	-22.2M	-23.54M	-22.37M	-20.71M	-18.43M	-14.43M	-9.9M	-8.38M	-8.67M	-6.99M	-5.43M	-5.43M
Selling & General & Admin	9.86M	9.97M	9.24M	9.4M	8.65M	7.53M	8.17M	7.94M	9.89M	6.98M	7.33M	6.43M	6.1M	3.85M	3.08M	2.17M	2M	1.27M	1.15M	1.15M
Research & Development	33.41M	31.26M	31.14M	27.67M	27.55M	22.19M	26.3M	23.1M	15.69M	18.96M	16.25M	15.72M	12.36M	10.51M	6.83M	6.22M	6.66M	5.7M	4.37M	4.37M
Other Expenses	n/a	n/a	-32.03M	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Operating Expenses	43.27M	41.23M	40.37M	37.07M	36.21M	29.72M	34.47M	31.04M	25.58M	25.94M	23.58M	22.15M	18.46M	14.36M	9.91M	8.39M	8.65M	6.97M	5.52M	5.52M
Interest Expense	n/a	n/a	n/a	n/a	n/a	n/a	n/a	4.45M	950K	799K	403K	480K	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Selling & Marketing Expenses	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cost & Expenses	43.27M	41.23M	41.27M	38.01M	36.94M	29.72M	34.47M	31.04M	25.58M	25.94M	23.58M	22.15M	18.46M	14.36M	9.91M	8.39M	8.65M	6.97M	5.52M	5.52M
Income Tax Expense	-1.87M	-1.86M	2.76M	1.83M	18.74M	-17.4M	13.85M	3.55M	-2.42M	-1.6M	-806K	-960K	-13K	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Shares Outstanding (Basic)	40.84M	40.63M	34.18M	33.5M	33.37M	33.28M	33.16M	32.37M	31.35M	31.3M	31.28M	31.25M	20.78M	28.31M	20.48M	20.48M	20.48M	20.48M	1.05M	1.05M
Shares Outstanding (Diluted)	43.05M	40.63M	35.51M	34.79M	33.37M	34.78M	33.16M	32.37M	31.35M	31.3M	31.28M	31.25M	20.78M	28.31M	20.48M	20.48M	20.48M	20.48M	1.05M	1.05M
EPS (Basic)	0.03	-0.35	1.61	0.70	-0.29	1.07	-0.78	-0.21	-0.71	-0.75	-0.72	-0.66	-0.89	-0.51	-0.48	-0.41	-0.42	-0.34	-5.18	-5.18
EPS (Diluted)	0.03	-0.35	1.55	0.68	-0.29	1.02	-0.78	-0.21	-0.71	-0.75	-0.72	-0.66	-0.89	-0.51	-0.48	-0.41	-0.42	-0.34	-5.18	-5.18
EBITDA	-4.88M	-21.66M	53.42M	22.05M	5.64M	14.01M	-15.57M	-5.24M	-25.05M	-25.42M	-23.12M	-21.76M	-18.1M	-14.06M	-9.66M	-8.19M	-8.55M	-6.88M	-5.45M	-5.45M
EBIT	-5.87M	-21.66M	57.79M	25.33M	9.2M	18.06M	-16.3M	-5.78M	-25.58M	-25.94M	-23.58M	-22.15M	-18.46M	-14.36M	-9.91M	-8.39M	-8.65M	-6.97M	-5.52M	-5.52M
Depreciation & Amortization	992K	n/a	900K	934K	736K	800K	700K	541K	525K	500K	466K	390K	364K	302K	252K	199K	98K	90K	69K	69K